Literature DB >> 9818335

Evaluation of in situ fracture versus phaco chop techniques.

J Ram1, T A Wesendahl, G U Auffarth, D J Apple.   

Abstract

PURPOSE: To quantify and compare the phaco time required using in situ nucleofracture and phaco chop techniques.
SETTING: Center for Research on Ocular Therapeutics and Biodevices and Miyake Laboratory, Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, USA.
METHODS: Thirty human eyes obtained postmortem were randomly divided into 2 groups of 15 eyes each. In situ nucleofracture or phaco chop was performed in each group. The phaco time required for each technique was determined.
RESULTS: The mean phaco time was 0.91 minutes +/- 0.37 (SD) for the phaco chop and 1.56 +/- 0.89 minutes for the in situ fracture technique (P < .015).
CONCLUSIONS: The phaco chop technique reduced phaco time and total phaco power consumed during phacoemulsification without imposing a risk of intraoperative complications.

Entities:  

Mesh:

Year:  1998        PMID: 9818335     DOI: 10.1016/s0886-3350(98)80167-3

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  3 in total

1.  Goat's eye integrated with a human cataractous lens: A training model for phacoemulsification.

Authors:  Sabyasachi Sengupta; Praveen Dhanapal; Manas Nath; Aravind Haripriya; Rengaraj Venkatesh
Journal:  Indian J Ophthalmol       Date:  2015-03       Impact factor: 1.848

2.  Microinterventional endocapsular nucleus disassembly: novel technique and results of first-in-human randomised controlled study.

Authors:  Tsontcho Ianchulev; David F Chang; Edward Koo; Susan MacDonald; Ernesto Calvo; Farrell Toby Tyson; Andrea Vasquez; Iqbal Ike K Ahmed
Journal:  Br J Ophthalmol       Date:  2018-04-18       Impact factor: 4.638

3.  Essentials of setting up a wet lab for ophthalmic surgical training in COVID-19 pandemic.

Authors:  Deepak Mishra; Karan Bhatia; Lalit Verma
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.